None
Quote | Trevi Therapeutics Inc. (NYSE:TRVI)
Last: | $ |
---|---|
Change Percent: | -3.42% |
Open: | $5.36 |
Close: | $5.0413 |
High: | $5.38 |
Low: | $4.82 |
Volume: | 4,689 |
Last Trade Date Time: | 02/12/2020 04:42:08 pm |
News | Trevi Therapeutics Inc. (NYSE:TRVI)
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference PR Newswire Professor Jacky Smith will present on the reduction of cough bouts with nalbuphine ER observed in patients with IPF in the CANAL trial NE...
Trevi Therapeutics to Participate in Upcoming April Events PR Newswire NEW HAVEN, Conn. , April 4, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio!...
Message Board Posts | Trevi Therapeutics Inc. (NYSE:TRVI)
Subject | By | Source | When |
---|---|---|---|
TRVI....................................https://stockcharts.com/h-sc/ui?s=TRVI&p | glenn1919 | investorshub | 04/22/2023 12:14:27 PM |
Uptick Network: $TRVI Trevi Therapeutics, Inc. News ~ Progress & 2022 Success of Clinical Studies fo | Uptick Network | investorshangout | 02/07/2023 4:50:35 PM |
Uptick Network: $TRVI updates! Trevi Therapeutics, Inc. Discusses Progress and 2022 Success of Clini | Uptick Network | investorshangout | 01/31/2023 10:58:24 AM |
Uptick Network: $TRVI News out! Trevi Therapeutics, Inc. ~ Progress and 2022 Success of Clinical Stu | Uptick Network | investorshangout | 01/30/2023 12:10:25 PM |
Uptick Network: $TRVI Trevi Therapeutics, Inc. Discusses Progress and 2022 Success of Clinical Studi | Uptick Network | investorshangout | 01/25/2023 5:41:17 PM |
News, Short Squeeze, Breakout and More Instantly...
Trevi Therapeutics Inc. Company Name:
TRVI Stock Symbol:
NYSE Market:
Trevi Therapeutics Inc. Website:
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference PR Newswire Professor Jacky Smith will present on the reduction of cough bouts with nalbuphine ER observed in patients with IPF in the CANAL trial NE...
Trevi Therapeutics to Participate in Upcoming April Events PR Newswire NEW HAVEN, Conn. , April 4, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio!...
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team PR Newswire Margaret Garin , MD, MSCR, joins team to advance the development of Haduvio in chronic cough indications NEW HAVEN, Conn. , April 2, 2024 /PRNewswir...